Tg Therapeutics (TGTX) EBT (2011 - 2026)

Tg Therapeutics' EBT history runs 16 years deep, the most recent figure standing at $20.4 million for Q1 2026.

• On a quarterly basis, EBT rose 272.4% year-over-year to $20.4 million in Q1 2026; TTM through Mar 2026 was $122.6 million, a 187.77% increase from a year earlier, with the FY2025 full-year figure at $107.7 million, up 307.02% from the prior year.
• EBT declined to $20.4 million in Q1 2026 per TGTX's latest filing, from $45.4 million in the prior quarter.
• Across five years, EBT topped out at $113.9 million in Q3 2023 and bottomed at -$83.8 million in Q4 2022.
• The 5-year median for EBT is $4.3 million (2024), against an average of -$5.2 million.
• Across the five-year window, EBT plunged 96.25% in 2024 and jumped 507.05% in 2025, its largest moves.
• Year by year, EBT stood at -$83.8 million in 2022, then surged by 83.27% to -$14.0 million in 2023, then soared by 287.72% to $26.3 million in 2024, then surged by 72.59% to $45.4 million in 2025, then tumbled by 55.19% to $20.4 million in 2026.
• Per Business Quant, the three latest TGTX EBT figures stand at $20.4 million (Q1 2026), $45.4 million (Q4 2025), and $25.9 million (Q3 2025).